Alvotech Announces Closing of Private Debt Financing
11 juil. 2024 04h45 HE
|
Alvotech
REYKJAVIK, Iceland, July 11, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech Announces Closing of Private Debt Financing
11 juil. 2024 04h45 HE
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing of its previously...
Alvotech kynnir jákvæða niðurstöðu virknirannsóknar á AVT03, fyrirhugaðri líftæknilyfjahliðstæðu við Prolia og Xgeva
02 juil. 2024 09h00 HE
|
Alvotech
Jákvæðar niðurstöður rannsóknarinnar sýna sambærilega klíníska virkni AVT03 og samanburðarlyfsins Prolia (denosumab) í sjúklingum Endapunktur var einnig uppfylltur í tveimur klínískum rannsóknum þar...
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
02 juil. 2024 09h00 HE
|
Alvotech
Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability...
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
02 juil. 2024 09h00 HE
|
Alvotech
Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability...
Alvotech Issues New Shares to Holders of Convertible Bonds
01 juil. 2024 17h35 HE
|
Alvotech
REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech gefur út nýja hluti í skiptum fyrir breytileg skuldabréf
01 juil. 2024 17h35 HE
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að fyrirtækið hefði gefið út nýja hluti í skiptum fyrir breytileg skuldabréf, sem upprunalega voru gefin út af Alvotech í nóvember og desember 2022 og voru með...
Alvotech Issues New Shares to Holders of Convertible Bonds
01 juil. 2024 17h35 HE
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued new shares to holders of subordinated...
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
01 juil. 2024 05h10 HE
|
Alvotech
REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
01 juil. 2024 05h10 HE
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced certain preliminary, unaudited key...